Clinical trials
Pulmonary Fibrosis clinical trials
Below are recruiting pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 143 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07790614Recruiting
Comparing two CT scan methods for identifying pulmonary fibrosis
This study compares two types of CT scans to see which one is better at identifying idiopathic pulmonary fibrosis (IPF), a specific type of interstitial lung disease. You may be able to join if you have been diagnosed with ILD and are being discussed by a team of specialists.
Rozzano, ItalyAges 18 years+ - NCT07743996Recruiting
Emotional and social experiences with fibrosis medications
This study looks at how people with pulmonary fibrosis feel emotionally and socially while taking antifibrotic medications like nintedanib or pirfenidone. It aims to understand the real-world impact of these treatments on daily life.
TokyoAges 40 years+ - NCT07679893RecruitingPhase 2
Inhaled nintedanib for idiopathic pulmonary fibrosis
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Windsor, OntarioAges 40–80 - NCT07707245Recruiting
Finding biomarkers in lung disease and lung cancer
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
Milan, MilanAges 18 years+ - NCT03437486Recruiting
Family study for inherited lung scarring causes
This study looks at what causes familial (inherited) pulmonary fibrosis by studying relatives who are not yet diagnosed with the lung disease. You may help researchers understand risk and early changes in the lungs within families.
Nashville, TennesseeAges 40–75 - NCT05310669Recruiting
Tests breathing effort using a nasal pressure sensor in IPF
This study measures how hard you breathe using a gentle nasal pressure device in people with idiopathic pulmonary fibrosis (IPF). It may help doctors better understand breathing mechanics in IPF and guide future care.
ModenaAges 18 years+ - NCT05382572Recruiting
Pulmonary fibrosis community registry for patients and families
This study builds a community registry to learn about people affected by pulmonary fibrosis and related lung conditions, including patients, caregivers, and close family. By joining, you help researchers better understand needs and experiences in the real world.
Chicago, IllinoisAges 18 years+ - NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT06122233Recruiting
Digital self-management for fibrotic lung disease
This trial tests whether a digital self-management program (using a smartphone or tablet) helps people with fibrotic interstitial lung disease better manage their symptoms and quality of life. If you have this lung condition and can use a mobile device, this study could offer you extra support at home.
Sydney, New South WalesAges 18 years+ - NCT06162884Recruiting
Using one scan to predict early scarred lung disease
This study uses a single lung scan to find early signs of progressive scarring (fibrosis) in people with pulmonary fibrosis. It may help doctors predict which patients will get worse faster.
Los Angeles, CaliforniaAges 18 years+ - NCT06189820RecruitingPhase 2
FAP protein as a marker for fibrotic lung disease
This trial is looking at a protein called FAP in the blood of people with fibrotic lung diseases. It aims to understand how this protein might be used as a marker to help doctors better diagnose and track these conditions.
BrusselsAges 18 years+ - NCT06251687Recruiting
Cryobiopsy for diagnosing progressive pulmonary fibrosis
This trial is testing a new, less invasive way to take a lung tissue sample (called transbronchial cryobiopsy) to help diagnose progressive pulmonary fibrosis (PPF). It may help doctors find the cause of your lung scarring without needing a larger surgery.
Beijing, Beijing MunicipalityAges 18–80 - NCT06238622RecruitingPhase 3
Long-term nerandomilast for pulmonary fibrosis follow-up
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
Birmingham, AlabamaAges 18 years+ - NCT06528418Recruiting
Breath test to find lung diseases
This study uses a simple breath test to detect different lung diseases. By analyzing the chemicals in your breath, researchers hope to find a faster, non-invasive way to diagnose lung conditions. It may be an option if you have a known lung disease and have a recent CT scan.
Guangzhou, GuangdongAges 18–100 - NCT06532071RecruitingPhase 2
Advanced MRI imaging for pulmonary fibrosis
This study tests whether advanced MRI scans can better detect and track lung scarring in people with certain types of pulmonary fibrosis. It may help doctors understand how well your treatment is working, without extra radiation from CT scans.
Boston, MassachusettsAges 18–80 - NCT06644144Recruiting
P4O2: A study for people with lung scarring
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
Amsterdam, North HollandAges 18–80 - NCT06702228Recruiting
Precision care for pulmonary fibrosis in Ireland
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
DublinAges 18–85 - NCT06883448Recruiting
Home monitoring for pulmonary fibrosis
This trial studies whether using a home monitoring program helps people with pulmonary fibrosis track their condition. It aims to make care easier and catch changes early.
AmsterdamAges 18 years+ - NCT07299695RecruitingPhase 3
IVIG for sudden worsening of IPF
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
PátraiAges 18 years+ - NCT07373288Recruiting
HOXB7 and lung markers in pulmonary fibrosis
This study looks at a protein called HOXB7 and other markers in lung tissue and blood to better understand pulmonary fibrosis. It may help researchers find new ways to diagnose or treat the disease.
ModenaAges 18–80 - NCT00515567Recruiting
Study lung tissue from people with lung scarring
This study uses lung tissue removed during lung transplant to learn more about lung scarring (pulmonary fibrosis). It can help researchers understand the disease better and improve future treatments.
Chicago, IllinoisAges 18 years+ - NCT04930289Enrolling by invitation
Lung transplant registry for better donor lung preservation
This study builds a worldwide database to track and improve how donor lungs are preserved before transplant. Your information may help doctors choose and manage donor lungs more effectively.
Phoenix, ArizonaAges Any age - NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Birmingham, AlabamaAges 18 years+ - NCT07284459RecruitingPhase 2
Testing PIPE 791 for idiopathic pulmonary fibrosis
This trial tests an investigational drug called PIPE 791 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug slows lung function decline, and you may continue your current IPF medicine.
Mar del Plata, Buenos AiresAges 40 years+
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Pulmonary Fibrosis trials by city
Studies with a site in or near these metro areas.
Pulmonary Fibrosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for pulmonary fibrosis?
- Yes. Clin2 currently lists 143 recruiting pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.